18:22:22 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaMERK Equities
Arctic Bioscience är verksamma inom läkemedelsbranschen. Bolaget är en utvecklare av diverse tillskott och tillsatser. Bolaget använder huvudsakligen fiskolja för att extrahera mineraler och näringsämnen, för att kunna behandla patienter som lider av psoriasis. Utöver huvudverksamheten erbjuds även färdiga produkter av omega-3 tillskott för privata aktörer samt företagskunder.


2022-08-25 Kvartalsrapport 2022-Q2
2022-05-06 Ordinarie utdelning ABS 0.00 NOK
2022-05-05 Årsstämma 2022
2022-04-07 Bokslutskommuniké 2021
2021-11-10 Extra Bolagsstämma 2021
2021-08-26 Kvartalsrapport 2021-Q2
2021-11-10 14:00:00

An extraordinary general meeting of Arctic Bioscience AS was held on 9 November 2021. All items on the agenda were approved by the Extraordinary General Meeting. 

Included on the agenda was the election of Marita Holstad as new board member.

Marita Holstad has a broad background from both the Norwegian and international pharmaceutical industry. She has significant experience from operational management positions in Norway, UK and the US, and currently holds position as VP, Medicine Commercialization Leader in GlaxoSmithKline (GSK), based in Chicago, IL. She will bring strategic management experience from both the development and launch of pharmaceutical products within dermatology and psoriasis.

Chairman Harald Nordal comments:

"The development of pharmaceutical products requires a long-term perspective. It demands good knowledge, solution-oriented talents and not least an ambitious cross-functional team and inspiring leaders with visions and networks that can be translated into clear operational goals. It is important to have a broadly composed board that can help navigate towards long-term results for patients, investors and other stakeholders, and it is a pleasure to have Marita joining Arctic Bioscience on this journey."

Marita Holstad comments:

"My excitement for Arctic Bioscience is multi-faceted. In general, it is exciting to join a Norwegian biopharmaceutical company, and it is especially exciting that the company uses marine resources to help develop treatments for some of the world's most widespread diseases such as psoriasis as well as extremely demanding diseases such as dementia and Alzheimer's. And of course, I am very proud that the company is locally anchored in Sunnmøre yet has big global ambitions.

Ever since I entered the Norwegian pharmaceutical industry back in 2000, I have had a desire to make a positive contribution - both in improving patients access to better medications, but also in helping young talents to learn about this industry and what it has to offer. Unfortunately, the industry in Norway has contracted over the years, while at the same time the need for continued efforts to conduct research and development has increased. Therefore, it is very rewarding to be able to contribute my experience to the development of Arctic Bioscience, and especially because it is locally based in my home region."

Minutes of the meeting and results of voting are attached and can also be found on the company's website www.arctic-bioscience.com.

This information is subject of the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.